Gallbladder Cancer: Can "Immunotherapy Duos" Finally Break the Resistance of Biliary Tumors? In 2026, the oncology world is buzzing about the success of Immunotherapy Combinations in treating biliary tract cancers. While the first generation of "checkpoint inhibitors" like Durvalumab provided a strong foundation, 2026 has seen the rise of "Double-Target" protocols that pair PD-L1 inhibitors with newer agents like CTLA-4 blockers. These "duos" work by simultaneously taking the brakes...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china